Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

SIMPLE SUMMARY: About 20% of patients with cancer who participate in a phase I clinical trial discontinue the trial early. Early trial discontinuation is undesirable both for the wellbeing of the patient as well as for the trial efficiency and the development of new anticancer drugs. We investigated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Douma, Joeri A. J., Buffart, Laurien M., Sedhom, Ramy, Labots, Mariette, Menke-van der Houven van Oordt, Willemien C., Skardhamar, Mikkjal, De Felice, Anthony, Lee, Esther, Dharmaraj, Divya, Azad, Nilofer S., Carducci, Michael A., Verheul, Henk M. W.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151105/
https://ncbi.nlm.nih.gov/pubmed/34064995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102304
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky